Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Burkitt Lymphoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Large B-Cell, Diffuse 2Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Biphenotypic, Acute 1Down Syndrome 1

Interventions

Dexamethasone 46Lenalidomide 30Bortezomib 24daratumumab 23pomalidomide 20Cyclophosphamide 16carfilzomib 15Specimen Handling 14Biopsy 14Calcium Dobesilate 12isatuximab 11Magnetic Resonance Spectroscopy 10talquetamab 9Melphalan 8iberdomide 7fludarabine 7belantamab mafodotin 6tocilizumab 5selinexor 5dexamethasone acetate 5dexamethasone 21-phosphate 5auricularum 5X-Rays 5fludarabine phosphate 4elotuzumab 4Sirolimus 4Nuclear Medicine Department, Hospital 4trametinib 3dabrafenib 3Whole-Body Irradiation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × prednylidene × 30 days × Clear all
NCT00602641 2026-05-29

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
306 enrolled 12 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡